NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $2.48 +0.38 (+18.10%) Closing price 04:00 PM EasternExtended Trading$2.48 +0.00 (+0.20%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Humacyte Stock (NASDAQ:HUMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Humacyte alerts:Sign Up Key Stats Today's Range$2.18▼$2.5550-Day Range$1.41▼$2.4852-Week Range$1.15▼$6.77Volume11.12 million shsAverage Volume3.97 million shsMarket Capitalization$392.76 millionP/E RatioN/ADividend YieldN/APrice Target$9.29Consensus RatingModerate Buy Company Overview Humacyte, Inc. is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications. The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation. Humacyte is also exploring additional indications, including peripheral and coronary artery bypass and central venous access, with the goal of addressing significant unmet medical needs in cardiovascular surgery and interventional medicine. Research and development efforts are supported by Good Manufacturing Practice (GMP) facilities in the United States, enabling scale-up from laboratory to commercial production. Founded in 2004 by Dr. Scott B. Rhodes at Duke University, Humacyte is headquartered in Durham, North Carolina, with ongoing clinical programs and partnerships extending into Europe and North America. The company is led by a management team with experience spanning cell therapy, regenerative medicine and vascular surgery. Humacyte continues to work alongside clinical investigators and strategic collaborators to advance its HAV technology toward regulatory approval and broad clinical adoption.AI Generated. May Contain Errors. Read More Humacyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreHUMA MarketRank™: Humacyte scored higher than 57% of companies evaluated by MarketBeat, and ranked 552nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialHumacyte has a consensus price target of $9.29, representing about 269.2% upside from its current price of $2.52.Amount of Analyst CoverageHumacyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Humacyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Humacyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.13% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Humacyte has recently increased by 2.26%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.13% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Humacyte has recently increased by 2.26%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.36 News SentimentHumacyte has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Humacyte this week, compared to 7 articles on an average week.Search Interest9 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows7 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,466,382.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Humacyte is held by insiders.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HUMA Stock News HeadlinesHumacyte announces publication of Symvess results in real-world combat1 hour ago | msn.comHumacyte rises after positive data from humanitarian study of Symvess1 hour ago | msn.comGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century.October 6 at 2:00 AM | Stansberry Research (Ad)Humacyte, Inc. Reports Zero Infections and High Patency Rates for Symvess in Military Medicine Journal Publication on Wartime Vascular Trauma TreatmentOctober 6 at 8:31 AM | quiverquant.comQHumacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™October 6 at 8:00 AM | globenewswire.comD. Boral Capital Maintains Humacyte (HUMA) Buy RecommendationSeptember 30, 2025 | msn.comHumacyte (HUMA) Price Target Increased by 51.64% to 9.44September 30, 2025 | msn.comHumacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered EsophagusSeptember 29, 2025 | globenewswire.comSee More Headlines HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $5.05 at the start of the year. Since then, HUMA stock has decreased by 50.2% and is now trading at $2.5150. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09. The company earned $0.30 million during the quarter, compared to analyst estimates of $0.94 million. Read the conference call transcript. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Humacyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/11/2025Today10/06/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HUMA CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees150Year Founded2004Price Target and Rating Average Price Target for Humacyte$9.29 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+342.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.70 million Net MarginsN/A Pretax Margin-7,171.27% Return on EquityN/A Return on Assets-78.26% Debt Debt-to-Equity Ratio2.97 Current Ratio2.45 Quick Ratio1.93 Sales & Book Value Annual Sales$818 thousand Price / Sales406.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.41) per share Price / Book-5.12Miscellaneous Outstanding Shares158,372,000Free Float150,295,000Market Cap$332.58 million OptionableOptionable Beta1.89 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HUMA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.